Agilent Technologies Inc. (NYSE: A) today announced it has completed the
acquisition of the BioSystem Development business. BioSystem Development
is a privately held company that develops and manufactures the AssayMAP
Microchromatography platform to meet the analytical needs of the life
sciences industry.
Agilent announced
the signing of an acquisition agreement on Dec. 1. Financial details of
the transaction were not disclosed.
As life science discovery and development continues to move toward a
better understanding of biological responses to disease, and has an
increased emphasis on protein-based therapeutics by pharmaceutical
companies, the need for automated, quality protein sample preparation
and analysis has become critical.
BioSystem Development’s AssayMAP platform, based on disposable
microchromatography cartridges, enables for the first time, automation
of complex, multi-step sample preparation workflows. These include
protein purification, characterization and analysis solutions for
bioprocess development, biomarker identification and analysis, as well
as a variety of other life science research applications.
The acquisition formalizes and streamlines the ongoing collaboration
between BioSystem Development and Agilent to combine AssayMAP technology
with Agilent's industry-leading automated liquid handling platforms, to
reduce discovery and development time and increase lab efficiency.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement
company and a technology leader in chemical analysis, life sciences,
electronics and communications. The company's 18,700 employees serve
customers in more than 100 countries. Agilent had net revenues of $6.6
billion in fiscal 2011. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
